Dr. Henry A. Ferreyra, MD

Dr. Ferreyra practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Ferreyra's NPI, 1669497822, was assigned on July 12, 2006. Dr. Ferreyra graduated from UC San Diego School of Medicine in 2000. Dr. Ferreyra holds California license A77921.

Dr. Ferreyra's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Ferreyra's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Ferreyra is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ferreyra practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Ferreyra's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Ferreyra is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Ferreyra is licensed in California.

Dmand AI lists age-related macular degeneration, cataract surgery with lens implant, dry eye, inflammation of iris, laser destruction of retinal or choroid lesions, retinal detachment, retinal occlusion and secondary membranaous cataract surgery among the conditions Dr. Ferreyra treats.

CMS data shows 12,714 Medicare services from Dr. Ferreyra across 14 procedure codes in 2024, for 527 Medicare patients. Medicare paid $711,616 for them. Every service was in an office.

CMS counts 527 Medicare patients who saw Dr. Ferreyra in 2024. The largest group is 75 to 84, with 201 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ferreyra's median patient age at 70, with 56% women.

In 2024, Dr. Ferreyra wrote 75 Medicare Part D claims for 30 patients. 61% of them were for generic drugs. CMS names the drug for 31 of them, across 2 drugs with 11 or more claims each, at $989 in total drug cost. In 2023, CMS named 75 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Ferreyra for performance year 2024, reported as part of a group. Dr. Ferreyra accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 38 papers to Dr. Ferreyra, published from 2008 to 2025. 2016 was the busiest year, with 3. The most frequent topics are Retinal Diseases, Macular Degeneration and Visual Acuity. Dr. Ferreyra has published most often in Retina. Dr. Ferreyra's most frequent co-authors are Kang Zhang, MD, William R. Freeman, MD and Shyamanga R. Borooah, MD.

Dmand AI links Dr. Ferreyra to 1 clinical trial. Conditions studied include Geographic Atrophy and Macular Degeneration. Open Payments lists research payments to Dr. Ferreyra that name 1 trial.

CMS Open Payments shows 20 general payments to Dr. Ferreyra from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Amgen Inc. paid the most, $110. It also lists 7 research payments totaling $973 in 2025, naming 1 clinical trial.

Dr. Ferreyra graduated from UC San Diego School of Medicine in 2000.

Dr. Ferreyra is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.